Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-07
2000-03-21
Stanton, Brian R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435 6, 435 691, 4351723, 536 245, 935 33, 935 65, A61K 4800, C12N 1511, C12N 1509
Patent
active
060402962
ABSTRACT:
A DNA comprises an oligonucleotide antisense to mRNA encoding an adenosine A.sub.1 or A.sub.3 receptor. The oligo is provided as a composition, various formulations, a capsule, and cartridge and in the form of a kit. The oligonucleotide of the invention is effective for reducing bronchoconstriction and/or allergy, and may be administered to a subject to treat respiratory ailments such as asthma and other conditions associated with the expression of adenosine receptors.
REFERENCES:
patent: 5225326 (1993-07-01), Bresser et al.
patent: 5245022 (1993-09-01), Weis et al.
patent: 5320962 (1994-06-01), Stiles et al.
Nyce, J.W., "Respirable Antisense Oligonucleotides as Novel Therapeutic Agents for Asthma and Other Pulmonary Diseases", Exp. Opin. Invest. Drugs, 6(9): 1-7, (1997).
Nyce, J.W. et al., "DNA Antisense Therapy for Asthma in an Animal Model", Nature, 385(20): 721-725, (1997).
Akhter, S. et al., "In Vivo Studies with Antisense Oligonucleotides", Trends in Pharmacol. Sciences, 18: 12-18, (1997).
Webb, A. et al., "BCL-2 Antisense Therapy in Patients with Non-Hodgkin Lymphoma", Lancet, 349(9059): 1137-41, (1997).
Yazaki, T. et al., "Treatment of Glioblastoma U-87 by Systemic Administration of an Antisense Protein Kinase C-Alpha Phosphorothioate Oligodeoynucleotide", Molecular Pharmacol., 50(2): 236-242, (1996).
Farmer, S.G. et al., "Adenosine Receptor-mediated Contraction and Relaxation of Guinea-pig Isolated Tracheal Smooth Muscle: Effects of Adenosine Antagonists", Br. J. Pharmacol., 95: 371-378 (1988).
Marquardt, D.L. et al., "Aminophylline Exposure Alters Mouse Bone Marrow-derived Mast Cell Adenosine Responsiveness", J. Allergy Clin Immunol. 78: 462-469, (1986).
Stull, R.A. et al., "Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices", Nucleic Acids Research, 20(13): 3501-3508 (1992).
Monia, B.P. et al., "Selective Inhibition of Mutant Ha-ras mRNA Expression by Antisense Oligonucleotides", J. Biol. Chem., vol. 2G7 No. 28, Issue of Oct. 5, 19954-19962 (1992).
Pasternak, Gavril W., "Molecular Neuropharmacology", The Scientist, 10(8):14 (1996).
Research Program--Antisense Technology, Novopharm Biotech-Research Program-Antisense Web Page, http://www.novopharmbiotech.ca/asense.htm.
Akhlar, S. et al., "In vivo studies with antisense oligonucleotides", Trends in Pharmacological Sciences, Current Techniques, 18:12-18, (1997).
Nyce, J.W., "Antisense oligonucleotides as emerging drugs", Emerging Drugs, 3:365-375, (1998).
Nyce, J.W., "Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases", Exp. Opin. Invest. Drugs 6(9):1149-1156 (1997).
J. Milligan et al.; Current Concepts in Antisense Drug Design. J. Med. Chem. 36(14): 1923-1937 (1993).
S. Ali et al.; Adenosine-induced bronchoconstriction in an allergic rabbit model:antagonism by theophylline aerosol. Agents Actions 37:165-167 (1992).
S. Ali et al.; Modification of allergen-induced airway obstruction and bronchial hyperresponsiveness in the allergic rabbit by theophylline aerosol. Agents Actions 37:168-170 (1992).
S. Ali et al.; Adenosine-Induced Bronchoconstriction and Contraction of Airway Smooth Muscle from Allergic Rabbits with Late-Phase Airway Obstruction: Evidence for an Inducible Adenosine A.sub.1 Receptor. J. Pharmacol. Exp. Therapeu. 268:1328-1334 (1994).
S. Ali et al.; Adenosine receptor-mediated bronchoconstriction and bronchial hyperresponsiveness in allergic rabbit model. Am. J. Physiol. 266:L271-277 (1994).
D.R. Sibley, et al; Transfected Mammalian Cell Lines Expressing the A1 Adenosine Receptor NTIS Field/Group Codes: 57F, 57B, 57Q 90D (Jun. 5, 1991).
Stull, et al. "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects," Pharmaceutical Research, vol. 12 (4): 465-483, Apr. 1995.
Wu Pong, S. "Oligonucleotides: Opportunities for Drug Therapy and Research," Pharmaceutical Technology, vol. 18: 102-114, Oct. 1994.
Miller, et al. "Gene Transfer and Antisense Nucleic Acid Techniques," Parasitiology Today, vol. 10 (3): 92-97, Mar. 1994.
Amzel Viviana
East Carolina University
Hauda Karen M.
Stanton Brian R.
LandOfFree
Specific antisense oligonucleotide composition & method for trea does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Specific antisense oligonucleotide composition & method for trea, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Specific antisense oligonucleotide composition & method for trea will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-730464